Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables and platform solutions to the worldwide life sciences industry,
this morning announced the featured interview of its president and CEO Richard
T. Schumacher with Stock Day’s Everett Jolly. Among other highlights,
Schumacher announced that the company has accomplished yet another important
milestone in the advancement of its proprietary Ultra Shear Technology (“UST”)
platform and commercialization program. Following the company’s recent news
regarding the development of the first working prototype of the UST system,
PBIO reported that it has developed a proprietary method for making high
quality, water-soluble oils. The company believes that this achievement will
open major new opportunities in multiple markets, including the CBD sector, and
will result in revenue generation in 2019.
“There are multiple products in many different markets that
we believe can benefit from nanoemulsions made by UST. These markets include
but are certainly not limited to, food and beverages, cosmetics,
pharmaceuticals, nutraceuticals, industrial lubricants, paints, and personal
care products such as sunscreens. However, because of the excellent data
generated to date, the clear need for water-soluble CBD oil, its current rapid
and exciting growth, and the potential to generate a strong return for our
shareholders, we have chosen to focus first on the CBD market. That said, we
plan to keep a very keen eye on the other markets as well,” Pressure
BioSciences president and CEO Richard T. Schumacher stated in
the interview.
To view the full press release, visit http://ibn.fm/1N81Y
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired PreEMT technology from BaroFold,
Inc. to allow entry into the biologics contract research services sector, and
(2) the use of its recently-patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
